ArticleInsights into imaging2025
The impact of sarcopenia on the progression of chronic non-bacterial osteomyelitis.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- "Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".Current opinion in rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesChronic non-bacterial osteomyelitis (CNO) is the most common autoinflammatory bone disease in children and adolescents. This study investigated the progression of CNO lesions during therapy and the potential impact of sarcopenia on disease progression, utilizing routine MRI.
methodsA retrospective analysis of MRI examinations was conducted on 29 children and adolescents with CNO. CNO lesions were segmented. Sarcopenia was assessed using the total psoas muscle index (PMI) at lumbar vertebral levels L3/4 and L4/5. Measurements were taken at four time points during the disease course (T1: baseline, T2-T4: follow-up). Based on the PMI, patients were classified as sarcopenic or non-sarcopenic, and the progression of CNO lesions and the impact of sarcopenia were analyzed.
resultsA total of 29 patients, aged 1-16 years, were included in the study, with 13 males and 16 females. Patients with sarcopenia had a significantly larger mean lesion area (868.95 mm
conclusionThe present study indicates that sarcopenia may serve as a negative prognostic factor in the treatment of CNO. Incorporating sarcopenia assessment as an additional parameter in routine whole-body MRI examinations could enhance the evaluation process. CRITICAL RELEVANCE STATEMENT: Sarcopenia can be assessed using routine whole-body MRI in patients with CNO and may serve as a negative prognostic factor, potentially enhancing the evaluation process. KEY POINTS: Whole-body MRI is crucial for diagnosing and monitoring CNO. Routine whole-body MRI in CNO patients can also be used to assess sarcopenia as an additional parameter. Sarcopenia may act as a negative prognostic factor in CNO treatment, potentially improving the evaluation process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.